Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matisyahu Shulman

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Addiction (Abingdon, England)|September 18, 2025
Thresholds for adjunctive medication usage and probability of initiating injectable naltrexoneKara E Rudolph, Shodai Inose, Nicholas T Williams, et al.
Drug and Alcohol Dependence|May 6, 2026
Beneficial effects of the rapid vs. standard procedure for injection naltrexone initiation operate through increased adjunctive medication useKara E Rudolph, Shodai Inose, Nicholas T Williams, et al.
Addiction (Abingdon, England)|August 5, 2024
Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patientsRachael K Ross, Edward V Nunes, Mark Olfson, et al.
Journal of Dental Education|June 12, 2021
Predoctoral substance use disorders curricula: A survey analysis and experiential pedagogyFolarin Odusola, Joshua Kaufman, Eva Turrigiano, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2024
Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patientsRachael K Ross, Edward V Nunes, Mark Olfson, et al.
Addiction Biology|December 8, 2021
Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUDAn-Li Wang, Matisyahu Shulman, Tse-Hwei Choo, et al.
Journal of Addiction Medicine|December 2, 2017
Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use DisordersEfrat Aharonovich, Aimee N C Campbell, Matisyahu Shulman, et al.
The American Journal on Addictions|June 8, 2025
Factors associated with receipt of second injection of naltrexone for opioid use disorder: Secondary analysis of 5 clinical trialsMatisyahu Shulman, Mei-Chen Hu, Maria A Sullivan, et al.
JAMA Network Open|October 4, 2024
Variation in Opioid Agonist Dosing in Clinical Trials by Race and EthnicityRachael K Ross, Shodai Inose, Matisyahu Shulman, et al.
Drug and Alcohol Dependence|February 8, 2022
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trialsMatisyahu Shulman, Mei-Chen Hu, Maria A Sullivan, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Addiction (Abingdon, England)|September 18, 2025
Thresholds for adjunctive medication usage and probability of initiating injectable naltrexoneKara E Rudolph, Shodai Inose, Nicholas T Williams, et al.
Drug and Alcohol Dependence|May 6, 2026
Beneficial effects of the rapid vs. standard procedure for injection naltrexone initiation operate through increased adjunctive medication useKara E Rudolph, Shodai Inose, Nicholas T Williams, et al.
Addiction (Abingdon, England)|August 5, 2024
Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patientsRachael K Ross, Edward V Nunes, Mark Olfson, et al.
Journal of Dental Education|June 12, 2021
Predoctoral substance use disorders curricula: A survey analysis and experiential pedagogyFolarin Odusola, Joshua Kaufman, Eva Turrigiano, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2024
Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patientsRachael K Ross, Edward V Nunes, Mark Olfson, et al.
Addiction Biology|December 8, 2021
Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUDAn-Li Wang, Matisyahu Shulman, Tse-Hwei Choo, et al.
Journal of Addiction Medicine|December 2, 2017
Neurocognitive Profiling of Adult Treatment Seekers Enrolled in a Clinical Trial of a Web-delivered Intervention for Substance Use DisordersEfrat Aharonovich, Aimee N C Campbell, Matisyahu Shulman, et al.
The American Journal on Addictions|June 8, 2025
Factors associated with receipt of second injection of naltrexone for opioid use disorder: Secondary analysis of 5 clinical trialsMatisyahu Shulman, Mei-Chen Hu, Maria A Sullivan, et al.
JAMA Network Open|October 4, 2024
Variation in Opioid Agonist Dosing in Clinical Trials by Race and EthnicityRachael K Ross, Shodai Inose, Matisyahu Shulman, et al.
Drug and Alcohol Dependence|February 8, 2022
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trialsMatisyahu Shulman, Mei-Chen Hu, Maria A Sullivan, et al.
Pageof 4